Status:
COMPLETED
Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
Lead Sponsor:
Barbara Ann Karmanos Cancer Institute
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Malignant Mesothelioma
Pulmonary Complications
Eligibility:
All Genders
25-80 years
Brief Summary
RATIONALE: Studying samples of body fluid and blood from patients who have been exposed to asbestos or vermiculite in the laboratory may help doctors learn more about changes that may occur in DNA and...
Detailed Description
OBJECTIVES: * Identify patients with known asbestos exposure at early stages of disease development (i.e., indolent premalignant pleural plaques and fibrosis vs malignant pleural mesothelioma). * Det...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Exposure to vermiculite or asbestos insulation
- Symptomatic or nonsymptomatic exposure-related disease
- Seen at a clinic in Libby, Montana (CARD Clinic) or Michigan (COEM)
- PATIENT CHARACTERISTICS:
- Not specified
- PRIOR CONCURRENT THERAPY:
- Not specified
Exclusion
Key Trial Info
Start Date :
January 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2013
Estimated Enrollment :
494 Patients enrolled
Trial Details
Trial ID
NCT00897247
Start Date
January 1 2007
End Date
October 1 2013
Last Update
March 5 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379